BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 27286261)

  • 21. Autophagy regulator BECN1 suppresses mammary tumorigenesis driven by WNT1 activation and following parity.
    Cicchini M; Chakrabarti R; Kongara S; Price S; Nahar R; Lozy F; Zhong H; Vazquez A; Kang Y; Karantza V
    Autophagy; 2014; 10(11):2036-52. PubMed ID: 25483966
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antimyeloma effects of a novel synthetic retinoid Am80 (Tamibarotene) through inhibition of angiogenesis.
    Sanda T; Kuwano T; Nakao S; Iida S; Ishida T; Komatsu H; Shudo K; Kuwano M; Ono M; Ueda R
    Leukemia; 2005 Jun; 19(6):901-9. PubMed ID: 15843826
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthetic retinoid Am80 up-regulates apelin expression by promoting interaction of RARα with KLF5 and Sp1 in vascular smooth muscle cells.
    Lv XR; Zheng B; Li SY; Han AL; Wang C; Shi JH; Zhang XH; Liu Y; Li YH; Wen JK
    Biochem J; 2013 Nov; 456(1):35-46. PubMed ID: 23992409
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MiR-128 regulation of glucose metabolism and cell proliferation in triple-negative breast cancer.
    Xiao M; Lou C; Xiao H; Yang Y; Cai X; Li C; Jia S; Huang Y
    Br J Surg; 2018 Jan; 105(1):75-85. PubMed ID: 29116653
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tamibarotene modulates the local immune response in experimental periodontitis.
    Jin Y; Wang L; Liu D; Lin X
    Int Immunopharmacol; 2014 Dec; 23(2):537-45. PubMed ID: 25448496
    [TBL] [Abstract][Full Text] [Related]  

  • 26. RAR agonists stimulate SOX9 gene expression in breast cancer cell lines: evidence for a role in retinoid-mediated growth inhibition.
    Afonja O; Raaka BM; Huang A; Das S; Zhao X; Helmer E; Juste D; Samuels HH
    Oncogene; 2002 Nov; 21(51):7850-60. PubMed ID: 12420222
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer.
    Liu X; Tang H; Chen J; Song C; Yang L; Liu P; Wang N; Xie X; Lin X; Xie X
    Oncotarget; 2015 Aug; 6(24):20070-83. PubMed ID: 26036638
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effective targeting of triple-negative breast cancer cells by PF-4942847, a novel oral inhibitor of Hsp 90.
    Mehta PP; Whalen P; Baxi SM; Kung PP; Yamazaki S; Yin MJ
    Clin Cancer Res; 2011 Aug; 17(16):5432-42. PubMed ID: 21715568
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo magnetic resonance imaging investigating the development of experimental brain metastases due to triple negative breast cancer.
    Hamilton AM; Foster PJ
    Clin Exp Metastasis; 2017 Feb; 34(2):133-140. PubMed ID: 28108861
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tamibarotene: a candidate retinoid drug for Alzheimer's disease.
    Fukasawa H; Nakagomi M; Yamagata N; Katsuki H; Kawahara K; Kitaoka K; Miki T; Shudo K
    Biol Pharm Bull; 2012; 35(8):1206-12. PubMed ID: 22863914
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Zerumbone suppresses the motility and tumorigenecity of triple negative breast cancer cells via the inhibition of TGF-β1 signaling pathway.
    Kim S; Lee J; Jeon M; Lee JE; Nam SJ
    Oncotarget; 2016 Jan; 7(2):1544-58. PubMed ID: 26637807
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disturbance of rapid eye movement sleep in senescence-accelerated mouse prone/8 mice is improved by retinoic acid receptor agonist Am80 (Tamibarotene).
    Kitaoka K; Sano A; Chikahisa S; Yoshizaki K; Séi H
    Neuroscience; 2010 May; 167(3):573-82. PubMed ID: 20138974
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice.
    Wu K; Zhang Y; Xu XC; Hill J; Celestino J; Kim HT; Mohsin SK; Hilsenbeck SG; Lamph WW; Bissonette R; Brown PH
    Cancer Res; 2002 Nov; 62(22):6376-80. PubMed ID: 12438218
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cripto-1 as a novel therapeutic target for triple negative breast cancer.
    Castro NP; Fedorova-Abrams ND; Merchant AS; Rangel MC; Nagaoka T; Karasawa H; Klauzinska M; Hewitt SM; Biswas K; Sharan SK; Salomon DS
    Oncotarget; 2015 May; 6(14):11910-29. PubMed ID: 26059540
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Suppression of invasion and metastasis of triple-negative breast cancer lines by pharmacological or genetic inhibition of slug activity.
    Ferrari-Amorotti G; Chiodoni C; Shen F; Cattelani S; Soliera AR; Manzotti G; Grisendi G; Dominici M; Rivasi F; Colombo MP; Fatatis A; Calabretta B
    Neoplasia; 2014 Dec; 16(12):1047-58. PubMed ID: 25499218
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peptide mediated active targeting and intelligent particle size reduction-mediated enhanced penetrating of fabricated nanoparticles for triple-negative breast cancer treatment.
    Hu G; Chun X; Wang Y; He Q; Gao H
    Oncotarget; 2015 Dec; 6(38):41258-74. PubMed ID: 26517810
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
    Amoury M; Kolberg K; Pham AT; Hristodorov D; Mladenov R; Di Fiore S; Helfrich W; Kiessling F; Fischer R; Pardo A; Thepen T; Hussain AF; Nachreiner T; Barth S
    Cancer Lett; 2016 Mar; 372(2):201-9. PubMed ID: 26806809
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The transcription factor MAFK induces EMT and malignant progression of triple-negative breast cancer cells through its target GPNMB.
    Okita Y; Kimura M; Xie R; Chen C; Shen LT; Kojima Y; Suzuki H; Muratani M; Saitoh M; Semba K; Heldin CH; Kato M
    Sci Signal; 2017 Apr; 10(474):. PubMed ID: 28400538
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of HJ-PI01 as a novel Pim-2 inhibitor that induces apoptosis and autophagic cell death in triple-negative human breast cancer.
    Zhao YQ; Yin YQ; Liu J; Wang GH; Huang J; Zhu LJ; Wang JH
    Acta Pharmacol Sin; 2016 Sep; 37(9):1237-50. PubMed ID: 27397540
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
    Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
    Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.